Tirzepatide

Tirzepatide (Zepbound, Mounjaro)  Tirzepatide is active ingredient in both Zepbound, and Mounjaro

Tirzepatide, received FDA approval for treating type 2 diabetes in May 2022. On November 08, 2023, it also received FDA approval of Zepbound for chronic weight management in adults with obesity or those who are overweight with at least one weight-related health condition. However, Tirzepatide can also be used for general weight management for individuals who want to prevent weight gain.

Tirzepatide is an innovative weight-loss medication that has gained significant attention for its effectiveness in combating obesity.  It belongs to the class of GLP-1 receptor ( glucagon-like peptide-1)  agonists . It also targets GIP receptors ( glucose-dependent insulinotropic peptide) agonists. Because both GLP-1 and GIP are so-called incretin hormones (substances produced in the body that stimulate beta cells in the pancreas to release insulin). The drug is sometimes also referred to as a “twincretin.” a feature not present in similar medications like Semaglutide.   This dual-action approach regulates appetite and is crucial in controlling blood sugar levels, making it a powerful tool for those struggling with weight loss.